“Global drug screening market projected to grow at a CAGR of 10.2% during the forecast period”
The drug screening market is expected to reach USD 8.63 billion million by 2022 from USD 5.32 billion in 2017, at a CAGR of 10.2%. Growing drug & alcohol consumption, enforcement of stringent laws mandating drug and alcohol testing, and the presence of government funding in major markets are factors driving the growth of the drug screening market. On the other hand, market growth may be limited to a certain extent due to the prohibition of workplace drug testing in some countries and the ban on alcohol consumption in several Islamic countries.
“Drug screening services are expected to grow at the highest CAGR during the forecast period”
Drug screening market is segmented into products and services. The services segment is projected to register the highest CAGR during the forecast period, growth in this segment is attributed to factors such as the growing drug and alcohol consumption worldwide, funding initiatives for drug testing laboratories, new and regular service launches and regulatory approvals, and the geographic expansion of drug and alcohol testing laboratories.
“By sample type, urine samples are expected to dominate the market during the forecast period”
The drug screening market is segmented into urine, breath, hair, oral, and other samples on the basis of sample type. The urine sample segment is expected to dominate the market during the forecast period due to the benefits it offers such as high accuracy in the detection of multiple drugs, cost-effectiveness, and instant results.
“Asia Pacific to witness high growth during the forecast period”
In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this regional segment is attributed to the growing consumption of illicit drugs, rising number of drunk-driving cases, growing awareness regarding drug screening tests and the strategic expansion of the market players in the region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 23%; Tier 2 - 32%; Tier 3 - 45%.
- By Designation: C-level- 21%; D-level- 36%; others--43%.
- By Region: North America-42%; Europe-37%; Asia Pacific-17%; RoW-4%.
List of companies profiled in the report
• Alere (US)
• Thermo Fisher (US)
• Dr?gerwerk (Germany)
• LabCorp (US)
• Quest Diagnostics (US)
• Alfa Scientific Designs (US)
• Lifeloc (US)
• MPD, Inc. (US)
• OraSure (US)
• Omega Laboratories (US)
• Premier Biotech (US)
• Psychemedics (US)
• Roche (Switzerland)
• Shimadzu (Japan)
• Seimens Healthineers (US)
The report provides an overview of the drug screening market. It aims at estimating the market size and growth potential of this market across different segments such as product and service, sample type, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in the drug screening market by providing them with the closest approximations of revenues for the overall market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies adopt suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.